Case Report: Anti–TNF-α therapy–associated destructive thyroiditis and unmasking of latent amyloid A amyloidosis in rheumatoid arthritis
Authors:
Open Access
- 25 February 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1768736
Abstract
Introduction: Tumor necrosis factor (TNF)-α inhibitors are widely used for rheumatoid arthritis (RA), but paradoxical immune reactions, including autoimmune thyroid disease, have been reported. Case presentation: We describe a 71-year-old man with a 16-year history of RA who developed destructive thyroiditis after initiation of certolizumab pegol. Despite symptom resolution, he subsequently developed acute renal failure and diarrhea. Biochemical and histological analyses revealed elevated serum amyloid A (AA) and amyloid deposition in the kidney and duodenum, confirming AA amyloidosis. We considered that the latent amyloidosis became clinically apparent following immune modulation by the anti-TNF-α biologic. Treatment with the IL-6 receptor antibody tocilizumab rapidly normalized inflammatory markers and improved both renal function and gastrointestinal symptoms. Conclusion: This case highlights that TNF-α inhibition may paradoxically unmask underlying amyloidosis and induce autoimmune thyroiditis. Clinicians should monitor thyroid and systemic amyloid markers when introducing biologic therapy for long-standing RA.Keywords
This publication has 31 references indexed in Scilit:
- Subacute thyroiditis in a patient with juvenile idiopathic arthritis undergoing etanercept treatment: a case report and review of the literatureModern Rheumatology, 2012
- Subacute, Silent, and Postpartum ThyroiditisMedical Clinics of North America, 2012
- Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritisClinical Rheumatology, 2010
- Autoimmune diseases induced by biological agentsAutoimmunity Reviews, 2010
- Interferon induced thyroiditisBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritisClinical Rheumatology, 2009
- Developing of granulomatous thyroiditis during etanercept therapyClinical Rheumatology, 2008
- A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditisThe Journal of Pathology, 2008
- Successful use of a humanized anti–interleukin‐6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritisArthritis & Rheumatism, 2006
- Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004